DanCann Pharma Expands with Tetra Pharm Collaboration
DanCann Pharma partners with Tetra Pharm Technologies to enhance cannabinoid therapies using ZYNDIKATE® technology.
Sammanfattning
DanCann Pharma and Tetra Pharm Technologies have entered a three-year agreement to integrate ZYNDIKATE® technology into DanCann's products, aiming to improve cannabinoid therapies in the Nordic markets.
DanCann Pharma, a leading Danish biopharmaceutical company, has announced a strategic partnership with Tetra Pharm Technologies to integrate the latter's ZYNDIKATE® drug delivery system into its cannabinoid-based products. This collaboration is set for an initial term of three years, with potential for extension, and aims to expand into other Nordic markets.
ZYNDIKATE® technology is engineered to enhance the bioavailability of lipophilic molecules like cannabinoids, optimizing their absorption and therapeutic efficacy. This innovation addresses the common challenges of oral administration of poorly soluble drugs, ensuring better patient outcomes.
Jeppe Krog Rasmussen, CEO of DanCann Pharma, expressed enthusiasm about the partnership, stating, 'This collaboration not only broadens our product range but also enhances the quality and consistency of treatments available to patients. We are excited about the potential of this partnership to set new standards in cannabinoid-based medicine.'
Martin Rose, CEO of Tetra Pharm Technologies, highlighted the significance of this alliance, noting, 'Our ZYNDIKATE® drug delivery technology enhances the bioavailability of lipophilic drugs, ensuring efficient absorption and targeted therapeutic effects. By partnering with DanCann Pharma, we aim to bring these advancements to a broader patient population in Denmark and, eventually, across the Nordic region.'
The first cannabinoid medicine utilizing ZYNDIKATE® technology is expected to be available to Danish patients by the first half of 2026. This development marks a significant milestone in DanCann's mission to offer innovative cannabinoid therapies.
From an investment perspective, this partnership could position DanCann Pharma as a frontrunner in the cannabinoid pharmaceutical industry, particularly in the Nordic markets. The integration of advanced drug delivery systems could lead to enhanced product offerings and potentially increased market share.
Given the promising outlook of this collaboration and the potential market expansion, the current recommendation is to hold DanCann Pharma's stock. While the partnership presents significant opportunities, investors should monitor the progress of product development and market penetration closely.
Källa
Sammanfattning
DanCann Pharma and Tetra Pharm Technologies have entered into a three-year agreement, with the possibility of extension, to integrate Tetra Pharm's ZYNDIKATE® drug delivery technology into DanCann's products. This technology is designed to improve the absorption and effectiveness of lipophilic molecules, such as cannabinoids, in the bloodstream. Both companies aim to expand this collaboration across the Nordic markets. The first product using this technology is expected to be available to Danish patients in the first half of 2026. DanCann Pharma focuses on cannabinoid-based medicines, while Tetra Pharm specializes in drugs for neurological and mental health disorders. The partnership seeks to enhance treatment quality and broaden the range of available therapies. The announcement includes forward-looking statements, which are subject to risks and uncertainties that could impact actual outcomes.
